The value of neoadjuvant therapy in changing the treatment mode of biliary tract cancers

ZHANG Xiao-fei,CUI Jiu-jie,LIU Ying-bin

DOI: https://doi.org/10.19538/j.cjps.issn1005-2208.2023.03.11

2023-01-01

Abstract:Biliary tract cancer（BTCs）is a highly malignant tumor that occurs in the biliary system. Surgical resection is the only potential cure option for BTCs, but only a few patients have the opportunity for surgical resection. In addition, nearly 50% of patients were considered resectable at the time of diagnosis, but failed to achieve R0 resection during exploratory laparotomy, and the recurrence rate of patients after R0 resection was still high, so the overall prognosis of cholangiocarcinoma was very poor. In recent years,neoadjuvant therapy has made great progress in many tumor types, which has the effect of lowering the stage before surgery,improving the R0 resection rate, reducing the risk of postoperative recurrence and distant metastasis and improving the survival rate, and has changed the treatment mode of the tumor. Many exploratory studies have been carried out on the neoadjuvant therapy of BTCs, but there is a lack of large sample, prospective,randomized controlled studies, and there are still some problems that have not been solved, including the exact efficacy of neoadjuvant therapy, the optimal number and time of treatment cycles, and the choice of postoperative adjuvant therapy. Compared with surgery alone, neoadjuvant therapy combined with surgery has a longer overall survival,but further prospective randomized controlled clinical studies are needed for verification to determine the optimal treatment plan and population, and to provide more clear information for clinical use. evidence-based medicine.